Thread by @ETimesLifestyle

Covaxin vs Covishield: Here's everything you must know about the two vaccines timesofindia.indiatimes.com/life-style/hea…

#CovidVaccine #CovidIndiaInfo #coronavirus

Currently, there are two vaccines available to the public- Bharat Biotech's Covaxin and Serum Institute- Oxford University-AstraZeneca's Covishield vaccine. Other vaccines, including Sputnik V, are soon touted to be made available.

#COVID19India #CovidVaccineIndia

Covaxin and Covishield are both homegrown vaccines that have driven India's vaccination drives. While Covaxin is fully made, developed and produced in India, Covishield is manufactured by Pune-based Serum Institute of India.
#COVID19India #CovidVaccineIndia

While Covishield, which is manufactured and marketed by Serum Institute of India is a viral vector vaccine that uses an adenovirus found in Chimpanzees, ChAD0x1, to deliver spike proteins and mount a tolerable immune response in response to a live virus.

#COVID19India

While Covaxin's second dose needs to be given 4-6 weeks after the first one, Covishield's second dose could be delayed, i.e. given 6-8 weeks after

#COVID19India #CovidVaccineIndia

Covishield carries an efficacy rate of 70%, which could be further scaled up to 90% if the dosing is given half a dose, followed by a full dose a month later. Covaxin, as per interim results and clinical studies, the Bharat Biotech vaccine was found to carry over 78% efficacy

Serum Institute of India has marked Covishield to be sold at ₹300 for the govt, and will be sold for ₹600 to private facilities. Covaxin is little expensive. For state govts, it will be marketed at ₹600, while for private hospitals and facilities, it will be priced at ₹1200.

Much like other vaccines, both Covaxin and Covishield carry reactogenic side effects. Covishield usage has sparked off the most controversies of late, with many countries pushing for a temporary halt over its use. As for Covaxin, complications have not been recorded yet

Covishield and Covaxin should also be monitored and then given to people with low platelets, or on steroid treatment. People who have been given monoclonal antibodies, or plasma therapy may also not be suitable candidates for vaccination right now.

Covaxin and Covishield both work effectively well to reduce the risk of symptomatic infections, severity and mortality, which is a major problem we are facing right now.